Drug-induced immune hemolytic anemia (DIIHA) can be caused by more than 100 types of drugs. Although DIIHA is a well-known condition, it cannot easily be diagnosed and it is usually misdiagnosed [1, 3] Simultaneous drug-induced immune hemolytic anemia (DIIHA) caused by multiple drugs is rare. We report a case of a patient who developed DIIHA caused by 2 drugs. The patient's serum exhibited agglutination of ceftizoxime-or sulbactam-coated red blood cells (RBCs; via a drug-adsorption mechanism) and of uncoated RBCs in the presence of sulbactam (via an immune-complex mechanism). Although ceftizoxime is known to exhibit a positive reaction by an immune-complex method with or without reactivity with drug-coated RBCs, this patient's antibodies were reactive only against drug-coated RBCs. On the other hand, sulbactam, which is known to cause hemolytic anemia by nonimmunologic protein adsorption, exhibited positive reactions in tests with both drug-coated RBCs and in the presence of sulbactam. This is the first report of DIIHA due to a sulbactam-cefoperazone combination and the fourth report of DIIHA due to ceftizoxime. Owing to the patient's complicated laboratory results, DIIHA was suspected only at a late stage. We propose that for the prompt diagnosis of DIIHA, tests for all possible causative drugs should be conducted by 2 methods. (Korean J Lab Med 2009;29:578-84) 
Simultaneous drug-induced immune hemolytic anemia (DIIHA) caused by multiple drugs is rare. We report a case of a patient who developed DIIHA caused by 2 drugs. The patient's serum exhibited agglutination of ceftizoxime-or sulbactam-coated red blood cells (RBCs; via a drug-adsorption mechanism) and of uncoated RBCs in the presence of sulbactam (via an immune-complex mechanism). Although ceftizoxime is known to exhibit a positive reaction by an immune-complex method with or without reactivity with drug-coated RBCs, this patient's antibodies were reactive only against drug-coated RBCs. On the other hand, sulbactam, which is known to cause hemolytic anemia by nonimmunologic protein adsorption, exhibited positive reactions in tests with both drug-coated RBCs and in the presence of sulbactam. This is the first report of DIIHA due to a sulbactam-cefoperazone combination and the fourth report of DIIHA due to ceftizoxime. Owing to the patient's complicated laboratory results, DIIHA was suspected only at a late stage. We propose that for the prompt diagnosis of DIIHA, tests for all possible causative drugs should be conducted by 2 methods. ( Korean J Lab Med 2009; 29:578-84) case of DIIHA. Furthermore, simultaneous immune responses to more than one drug are exceptionally rare [2] .
We report a case of a patient who exhibited drug-induced antibodies with unusual mechanisms of reactivity against both ceftizoxime and cefobactam. Therefore, we propose that experiments should be conducted on both drug-coated red blood cells (RBCs) and uncoated RBCs for a patient with DIIHA, in the presence of each possible causative drug that the patient has been administered.
CASE REPORT

Patient history
A 49-yr-old woman was transferred to our hospital for the treatment of a large skin injury she had incurred during a traffic accident. In the previous hospital, DATs yielded negative results before antibiotic treatment was initiated. On admission to our hospital, the patient' s hemoglobin (Hb) level was 5.7 g/dL, and her absolute reticulocyte count was 86.6×10
3 cells/mL (reticulocyte proportion, 4.8%) ( Table 1 ). Contrary to the negative DAT results obtained at the previous hospital, the DAT performed at our hospital yielded positive results for anti-IgG antibodies (3+) and negative results for anti-C3d antibodies on hospitalization day (HD) 6. Furthermore, the unexpected antibody screening and identification tests revealed panagglutination with a positive auto-control. Ceftizoxime treatment (1g q 12 hr, iv), which was administered from the time of admission to HD 10, was discontinued and replaced with cefobactam treatment (1g q 8 hr, iv). On HD 18, vancomycin (1g q 12 hr, iv) was included in the regimen to treat a cutaneous wound infection (Fig. 1 ).
The Hb levels, which increased (from 5.7 g/dL to 6.8 g/ 
Blood samples and drugs for antibody testing
Blood was collected in serum separation tubes at various time points during the hospitalization period. Most of the drugs considered for drug-dependent antibody testing were exactly the same as those that were intravenously administered to the patient, except for sulbactam and cefoperazone, which were purchased from other companies but had the same constitutional formulas and no additives.
To determine the effect of IgG on the reactivity of beta-lactamase-coated RBCs, the serum IgG level was measured using nephelometry (Dade Behring BN II nephelometer, Mahburg, Germany). 
Antiglobulin testing
Testing in the presence of drugs
The patient' s serum was tested using an immune-complex method, according to the reference protocol [12] . In brief, the patient' s serum, a pool of fresh normal sera from (Table 3) .
Negative results were obtained with the eluate.
DISCUSSION
DIIHA is a very rare and under-diagnosed condition [1, 3, 13] . In practice, when clinicians suspect DIIHA, they simply discontinue treatment with the possible causative drugs and switch to other drugs. However, DIIHA can occur again on treatment with the new drugs. The best way to avoid this complication is to confirm DIIHA by in vitro analysis if the patient has prolonged anemia and DIIHA is suspected. DIIHA caused by multiple drugs is extremely rare. In one previous study, only 1 of 73 DIIHA cases were found
The drugs and reagents were reacted with ficin-treated RBCs, and the results were assessed after incubation at 37℃ and during the antiglobulin phase. *Tested with serum diluted 1:2 Abbreviations: Pt's, patient's; AB serum, pooled normal AB serum for complement; PBS, phosphate-buffered saline; NT, not tested. to be caused by multiple drugs [2] . Except for HIV-associated IHA [14] , no specific condition has been shown to be associated with the production of antibodies against multiple drugs. The patient in the present case had been healthy before being admitted to the hospital after the car accident.
Reagents in the tubes
The mechanisms of drug-dependent IHA can be classi- Further, switching to another drug may hasten the recovery process.
